Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment.
